MX2017005306A - Novedosos sitios de integracion en celulas cho y usos de estos. - Google Patents

Novedosos sitios de integracion en celulas cho y usos de estos.

Info

Publication number
MX2017005306A
MX2017005306A MX2017005306A MX2017005306A MX2017005306A MX 2017005306 A MX2017005306 A MX 2017005306A MX 2017005306 A MX2017005306 A MX 2017005306A MX 2017005306 A MX2017005306 A MX 2017005306A MX 2017005306 A MX2017005306 A MX 2017005306A
Authority
MX
Mexico
Prior art keywords
expression
integration
cho cells
new sites
eukaryotic
Prior art date
Application number
MX2017005306A
Other languages
English (en)
Spanish (es)
Inventor
Chen Gang
Burakov Darya
Shen Ying
P Fandl James
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54602002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005306(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017005306A publication Critical patent/MX2017005306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
MX2017005306A 2014-10-23 2015-10-21 Novedosos sitios de integracion en celulas cho y usos de estos. MX2017005306A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067774P 2014-10-23 2014-10-23
PCT/US2015/056653 WO2016064999A1 (en) 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof

Publications (1)

Publication Number Publication Date
MX2017005306A true MX2017005306A (es) 2018-01-09

Family

ID=54602002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005306A MX2017005306A (es) 2014-10-23 2015-10-21 Novedosos sitios de integracion en celulas cho y usos de estos.

Country Status (16)

Country Link
US (5) US9816110B2 (enExample)
EP (1) EP3209785B1 (enExample)
JP (1) JP6668340B2 (enExample)
KR (1) KR102243243B1 (enExample)
CN (1) CN107109434B (enExample)
AR (1) AR102420A1 (enExample)
AU (1) AU2015335921B2 (enExample)
BR (1) BR112017008022A2 (enExample)
CA (1) CA2965495C (enExample)
EA (1) EA037255B1 (enExample)
IL (1) IL251674B (enExample)
MX (1) MX2017005306A (enExample)
MY (1) MY184103A (enExample)
SG (1) SG11201703149RA (enExample)
TW (2) TWI747808B (enExample)
WO (1) WO2016064999A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209785B1 (en) 2014-10-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof
US10329594B1 (en) 2015-09-03 2019-06-25 CHO Plus, Inc. Cell lines for high level production of protein-based pharmaceuticals
US11649449B2 (en) 2015-09-03 2023-05-16 CHO Plus, Inc. Hybrid cell lines for high level production of a target protein
BR112018071283A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
US11530277B2 (en) * 2016-04-20 2022-12-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP2020501593A (ja) * 2016-12-20 2020-01-23 ディベロップメント センター フォー バイオテクノロジーDevelopment Center For Biotechnology 改変細胞、調製方法、及び構築物
WO2018148196A1 (en) * 2017-02-07 2018-08-16 Sigma-Aldrich Co. Llc Stable targeted integration
WO2018150271A1 (en) * 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
US11959093B2 (en) 2017-03-19 2024-04-16 Applied Stemcell, Inc. Integration sites and uses thereof
KR102531749B1 (ko) * 2017-08-11 2023-05-10 베링거 인겔하임 인터내셔날 게엠베하 Cho 세포 내 통합 부위
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
WO2019126562A1 (en) * 2017-12-22 2019-06-27 Bio-Rad Laboratories, Inc. Controlling phenotype of organisms with crispr/cas gene targeting
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
CN109295092B (zh) * 2018-10-30 2021-06-29 江南大学 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用
CN109136193B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用
CN109337927B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用
CN109295093B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用
CN109321604B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用
CN109207432B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用
EP3980544A1 (en) * 2018-12-21 2022-04-13 F. Hoffmann-La Roche AG Targeted integration of nucleic acids
SG11202110076PA (en) * 2019-04-02 2021-10-28 Chugai Pharmaceutical Co Ltd Method of introducing target-specific foreign gene
EP3990649A1 (en) 2019-06-26 2022-05-04 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
EP3901266A1 (en) * 2020-04-22 2021-10-27 LEK Pharmaceuticals d.d. Super-enhancers for recombinant gene expression in cho cells
JP7887833B2 (ja) * 2020-06-02 2026-07-10 キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー 遺伝子挿入用の複数のドックを有している細胞株
KR20230027043A (ko) * 2020-06-24 2023-02-27 제넨테크, 인크. 핵산의 표적화 통합
WO2022079083A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for va rna transcription
CN113755447B (zh) * 2021-09-23 2022-04-29 云舟生物科技(广州)股份有限公司 一种用于生产腺病毒的293a细胞株及其制备与应用
CN118159660A (zh) 2021-10-18 2024-06-07 瑞泽恩制药公司 多核苷酸的受控转录
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
US20250098652A1 (en) * 2022-01-28 2025-03-27 The Trustees Of Columbia University In The City Of New York Genetic Modifications for Xenotransplantation
CN117305334B (zh) * 2022-06-21 2024-11-08 深圳太力生物技术有限责任公司 靶向整合细胞及其制备方法、生产目标基因表达产物的方法
US20240168018A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and evaluating viruses and virus-like particles
CN118726475B (zh) * 2023-03-28 2025-07-08 深圳太力生物技术有限责任公司 核酸、重组载体、靶向整合细胞、基因表达方法和应用
WO2024211287A1 (en) * 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
CN121794393A (zh) 2023-09-07 2026-04-03 里珍纳龙药品有限公司 经共价表面修饰的腺相关病毒的生产和纯化
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
WO2026050618A1 (en) 2024-08-29 2026-03-05 Regeneron Pharmaceuticals, Inc. Polynucleotide constructs and cell lines for recombinant aav production
WO2026162509A1 (en) 2025-01-28 2026-08-06 Selexis Sa Integration regions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
ES2375266T3 (es) 1998-07-21 2012-02-28 Millipore Corporation Un polinucleótido que comprende un elemento de apertura de cromatina ubicuo (ucoe).
US6521419B1 (en) * 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
AU2002254529A1 (en) 2001-04-04 2002-10-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Nucleic acids for transgene expression
US20040045043A1 (en) * 2002-05-20 2004-03-04 Finney Robert E. Compositions and methods for generating conditional knockouts
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
DK2150617T3 (en) * 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
EP3156494B8 (en) * 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
CA2832095A1 (en) 2011-04-05 2012-10-11 The Scripps Research Institute Chromosomal landing pads and related uses
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP3683319A1 (en) * 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
US9222105B2 (en) * 2011-10-27 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
EP3209785B1 (en) 2014-10-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof

Also Published As

Publication number Publication date
JP2017535258A (ja) 2017-11-30
CN107109434B (zh) 2026-05-26
CA2965495A1 (en) 2016-04-28
EA201790698A1 (ru) 2018-01-31
TW202144576A (zh) 2021-12-01
MY184103A (en) 2021-03-18
BR112017008022A2 (pt) 2018-02-20
IL251674A0 (en) 2017-06-29
EP3209785A1 (en) 2017-08-30
JP6668340B2 (ja) 2020-03-18
SG11201703149RA (en) 2018-02-27
US20180030480A1 (en) 2018-02-01
US12565667B2 (en) 2026-03-03
WO2016064999A1 (en) 2016-04-28
EP3209785B1 (en) 2019-07-31
AR102420A1 (es) 2017-03-01
US20210171984A1 (en) 2021-06-10
TWI747808B (zh) 2021-12-01
KR102243243B1 (ko) 2021-04-22
KR20170096999A (ko) 2017-08-25
IL251674B (en) 2020-10-29
US11268109B2 (en) 2022-03-08
US20200002732A1 (en) 2020-01-02
US11788102B2 (en) 2023-10-17
US9816110B2 (en) 2017-11-14
US20240018553A1 (en) 2024-01-18
AU2015335921B2 (en) 2020-06-25
TWI780847B (zh) 2022-10-11
EA037255B1 (ru) 2021-02-26
CA2965495C (en) 2022-05-24
AU2015335921A1 (en) 2017-05-04
CN107109434A (zh) 2017-08-29
TW201629229A (zh) 2016-08-16
US20160115502A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
AR102420A1 (es) Sitios de integración en celulas cho y sus usos
MX2020004541A (es) Edicion de genes de celulas primarias.
CY1124627T1 (el) Στοχευμενη τροποποιηση γονιδιωματος αρουραιου
CO2019013609A2 (es) Vectores de neoantígeno de alfavirus
MX2017011679A (es) Polipeptidos de transposasa y sus usos.
PH12019501130A1 (en) Viral delivery of neoantigens
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
SA523441205B1 (ar) التحرير المتعدد للجينوم
MX2022009512A (es) Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
MX2017008190A (es) Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
GB2550745A (en) Crispr hybrid DNA/RNA Polynucleotides and methods of use
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
GB201609811D0 (en) Methods, cells, systems, arrays, RNA and kits
BR112019005748A2 (pt) afinidade-conjugados de oligonucleotídeo e usos destes
BR112018074531A2 (pt) uso de proteínas de ligação a dna programáveis para realçar a modificação do genoma-alvo
AR103225A1 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
MX2016007797A (es) Metodos para integracion genomica.
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
TN2019000124A1 (en) Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
BR112015030972A8 (pt) células sc-beta e composições e métodos para geração das mesmas
ECSP14028704A (es) Métodos y composiciones para la modificación de adn objetivo dirigida por arn y para la modulación de la transcripción dirigida por arn
MY181693A (en) Dual quencher probes
PH12021550173A1 (en) Improved thymidine kinase gene